Literature DB >> 2010538

Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.

A M Randi1, I Rabinowitz, D J Mancuso, P M Mannucci, J E Sadler.   

Abstract

Many variants of von Willebrand disease (vWD) with qualitatively abnormal von Willebrand factor (vWF) are recognized. In vWD type IIB, the abnormal protein displays enhanced affinity for a platelet vWF receptor, the glycoprotein Ib-IX complex. 14 patients from 7 unrelated families with vWD type IIB were studied to determine the molecular basis for this phenotype. Specific oligonucleotide primers were used to amplify portions of vWF exon 28 encoding a domain that interacts with the platelet glycoprotein Ib-IX complex. Candidate missense mutations were identified for all 14 patients by DNA sequencing, allele specific oligonucleotide hybridization, and restriction endonuclease digestion. These sequence changes occur in an 11 amino acid segment within a single disulfide loop bounded by Cys(509) and Cys(695). All of these sequence changes are C----T transitions within CG dinucleotides. Six patients from two unrelated families were heterozygous for the encoded sequence Arg(543)----Trp. Seven patients from four unrelated families were heterozygous for the encoded sequence Arg(545)----Cys; this sequence change appears to have occurred independently three times, once as a new spontaneous mutation. One patient with apparently sporadic vWD type IIB was heterozygous for the encoded sequence Val(553)----Met, and this appears to be a new mutation. None of these sequence changes was found in 100 normal alleles. These findings suggest that vWD type IIB may be caused by relatively few distinct mutations, that these mutations may cluster within a specific region of one disulfide loop in vWF domain A1, and that this region can modulate the affinity of vWF for the platelet glycoprotein Ib-IX complex.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2010538      PMCID: PMC295140          DOI: 10.1172/JCI115122

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots.

Authors:  H Youssoufian; H H Kazazian; D G Phillips; S Aronis; G Tsiftis; V A Brown; S E Antonarakis
Journal:  Nature       Date:  1986 Nov 27-Dec 3       Impact factor: 49.962

2.  Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease.

Authors:  M E Rick; S B Williams; R A Sacher; L P McKeown
Journal:  Blood       Date:  1987-03       Impact factor: 22.113

3.  Molecular basis of base substitution hotspots in Escherichia coli.

Authors:  C Coulondre; J H Miller; P J Farabaugh; W Gilbert
Journal:  Nature       Date:  1978-08-24       Impact factor: 49.962

4.  Base composition-independent hybridization in tetramethylammonium chloride: a method for oligonucleotide screening of highly complex gene libraries.

Authors:  W I Wood; J Gitschier; L A Lasky; R M Lawn
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

5.  Cloning and characterization of two cDNAs coding for human von Willebrand factor.

Authors:  J E Sadler; B B Shelton-Inloes; J M Sorace; J M Harlan; K Titani; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

6.  Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

7.  Carrier detection of Hemophilia B by using a restriction site polymorphism associated with the coagulation Factor IX gene.

Authors:  L Grunebaum; J P Cazenave; G Camerino; C Kloepfer; J L Mandel; P Tolstoshev; M Jaye; H De la Salle; J P Lecocq
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

8.  von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib.

Authors:  Y Fujimura; K Titani; L Z Holland; S R Russell; J R Roberts; J H Elder; Z M Ruggeri; T S Zimmerman
Journal:  J Biol Chem       Date:  1986-01-05       Impact factor: 5.157

9.  Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation.

Authors:  L De Marco; A Girolami; T S Zimmerman; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

10.  Heterogeneity in type IIB von Willebrand disease: two unrelated cases with no family history and mild abnormalities of ristocetin-induced interaction between von Willebrand factor and platelets.

Authors:  A B Federici; P M Mannucci; R Bader; R Lombardi; A Lattuada
Journal:  Am J Hematol       Date:  1986-12       Impact factor: 10.047

View more
  21 in total

Review 1.  Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders.

Authors:  Antonio Girolami; Elisabetta Cosi; Silvia Ferrari; Annamaria Lombardi; Fabrizio Fabris
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

3.  Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease.

Authors:  E W Murray; A R Giles; D Lillicrap
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

Review 4.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

5.  Molecular and clinical profile of type 2 von Willebrand disease in Iran: a thirteen-year experience.

Authors:  Maryam Rassoulzadegan; Fereydoun Ala; Mohammad Jazebi; Mohammad Said Enayat; Shadi Tabibian; Mahmood Shams; Mehran Bahraini; Akbar Dorgalaleh
Journal:  Int J Hematol       Date:  2020-01-14       Impact factor: 2.490

6.  Seeming homozygosity in type-IIB von Willebrand's disease due to a polymorphism within the sequence of a commonly used primer.

Authors:  J C Eikenboom; P H Reitsma; E Briët
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

7.  Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence.

Authors:  J C Eikenboom; T Vink; E Briët; J J Sixma; P H Reitsma
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

8.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment.

Authors:  M Murata; S R Russell; Z M Ruggeri; J Ware
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.